The Latest Breaking News from CME Group

CME Group (NASDAQ:CME) has outperformed the market over the past 10 years by 3.58% on an annualized basis producing an average annual return of 14.53%. Currently, CME Group has a market capitalization of $75.33 billion.

CME Group's (NASDAQ:CME) short percent of float has fallen 18.92% since its last report. The company recently reported that it has 3.24 million shares sold short, which is 0.9% of all regular shares that are available for trading.

A group is seeking regulatory approval for the Intelligent Medicine Exchange, which could help participants hedge risks from rising medical costs.

CME Group (NASDAQ:CME) has outperformed the market over the past 10 years by 2.35% on an annualized basis producing an average annual return of 14.45%. Currently, CME Group has a market capitalization of $71.41 billion.

Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of $5.92. Molecular Partners closed at $6.88 at the end of the last trading period.

Canada has long been one of the world’s top wheat exporters, with the majority of that the Canadian Western Red Spring variety. On the horizon: a new tool for participating in that market.

Over the past 3 months, 11 analysts have published their opinion on CME Group (NASDAQ:CME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Upgrades

Cobalt and lithium demand have surged as electric car sales more than doubled between 2020 and 2021. It’s one of four green trends we’re watching for 2022.